Transplantation of normal bone marrow from C3H/HeN nu/nu (H-2k) mice into young MRL/MPlpr/lpr (MRL/I; H-2k) mice (<1.5 mo) prevented the development of autoimmune diseases and characteristic thymic abnormalities in the recipient mice. When female MRL/1 (>2 mo) or male BXSB (H-2b) mice (9 mo) with autoimmune diseases and lymphadenopathy were lethally irradiated and then reconstituted with allogeneic bone marrow cells from young BALB/c nu/nu (H-2d) mice (<2 mo), the recipients survived for more than 3 mo after the bone marrow transplantation and showed no graft-versus-host reaction. Histopathological study revealed that lymphadenopathy disappeared and that all evidence of autoimmune disease either was prevented from developing or was completely corrected even after its development in such mice. All abnormal T-cell functions were restored to normal. The newly developed T cells were found to be tolerant of both bone marrow donor-type (BALB/c) and host-type (MRL/I or BXSB) major histocompatibility complex (MHC) determinants. Therefore, T-cell dysfunction in autoimmuneprone mice can be associated with both the involutionary changes that occur in the thymus of the autoimmune-prone mice and also to abnormalities that reside in the stem cells.
BALB/c nu/nu (H-2d) mice (<2 mo), the recipients survived for more than 3 mo after the bone marrow transplantation and showed no graft-versus-host reaction. Histopathological study revealed that lymphadenopathy disappeared and that all evidence of autoimmune disease either was prevented from developing or was completely corrected even after its development in such mice. All abnormal T-cell functions were restored to normal. The newly developed T cells were found to be tolerant of both bone marrow donor-type (BALB/c) and host-type (MRL/I or BXSB) major histocompatibility complex (MHC) determinants. Therefore, T-cell dysfunction in autoimmuneprone mice can be associated with both the involutionary changes that occur in the thymus of the autoimmune-prone mice and also to abnormalities that reside in the stem cells.
However, normal stem cells from BALB/c nu/nu donors can differentiate into normal functional T cells even in mice whose thymus had undergone considerable involution, as in the case of BXSB or MRL/I mice in the present studies. These findings suggest that marrow transplantation may be a strategy ultimately to be considered as an approach to treatment of lifethreatening autoimmune diseases in humans. T-cell dysfunction in autoimmune-prone mice previously attributed to involutionary changes that occur in the thymus of these mice may instead be attributed to abnormalities that basically reside in the stem cells of the autoimmune-prone mice.
The availability of several murine strains that develop systemic lupus erythematosus-like disease has prompted efforts to gain better understanding of the fundamental nature of autoimmune diseases through extensive studies of the immunological abnormalities of these mice. MRL/MP-lpr/lpr (MRL/l) and BXSB mice as well as NZB mice and NZB x NZW F1 hybrids spontaneously develop autoimmune diseases characterized by anti-double-stranded (ds) DNA antibodies, immune-complex glomerulonephritis, and death from renal failure (1) . Abnormalities have been found in or attributed to T cells, thymic epithelium, B cells, and/or macrophages in these mice (2) (3) (4) (5) (6) (7) (8) . Recently, several groups have shown that the proneness to develop autoimmune diseases actually resides in defects at the lymphoid stem-cell level and that defects of function are not directly attributable to environmental factors such as hormones or viruses (9) (10) (11) .
Therefore, we examined whether or not transfer of normal stem cells into autoimmune-prone mice can be used to both prevent and treat autoimmune diseases.
In the present study, we show that allogeneic bone marrow transplantation from donors carrying the nu/nu genes permits both prevention and effective treatment of autoimmune diseases in both MRL/l and BXSB mice and that normal T cells, B cells, and macrophages developed in such mice transplanted with allogeneic bone marrow 3 mo after the bone marrow transplantation.
MATERIALS AND METHODS
Mice. Inbred MRL/l, MRL/MP-+/+ (MRL/n), and BXSB mice were obtained from The Jackson Laboratory. BALB/c nu/nu, BALB/c, C3H/HeN nu/nu, C3H/HeN, and DBA/2 mice were obtained from the Central Institute for Experimental Animals (Tokyo). These mice were maintained under specific pathogen-free conditions in our facilities.
Bone Marrow Transplantation. MRL/l and BXSB mice were irradiated (850 rads for MRL/l and 950 rads for BXSB from a cobalt-60 source) and reconstituted by intravenous injection of 2 x 107 bone marrow cells from young BALB/c nu/nu mice (<2 mo). These MRL/l and BXSB mice were usually sacrificed more than three months after bone marrow transplantation. Testing with anti-H-2 antisera and complement indicated that more than 90% of spleen cells were of donor type. Cell Separation. Mice were sacrificed by cervical dislocation. The spleens were removed aseptically, minced, and gently passed through a fine mesh stainless-steel sieve into phosphate-buffered saline.
Cytotoxic Test. Spleen cells that were suspended in TC-199 (GIBCO) with 5% fetal calf serum (Microbiological Associates) were adjusted to 5 x 106 cells per ml and divided into two aliquots of 50 ,ul. The cells were incubated with 50 ,ul of a 1:10 dilution of anti-Thy-1.2 antibody for 30 min at 4°C. The cells were then washed once and resuspended in 100 ,ul of a 1:10 dilution of rabbit complement (Cedarlane Laboratories, Hornby, ON, Canada) previously absorbed with mouse spleen cells. After a 30-min incubation at 37°C, the viability of the cells was determined by trypan blue dye-exclusion test. The counts were converted to a cytotoxic index by the formula:
CI =% V cells (C alone) -% V cells (Ab + C) x 100 % V cells (C alone) in which C represents complement; Ab, antibody; CI, cytotoxic index; and V cells, viable cells.
Abbreviations: MRL/l, MRL/MP-lpr/lpr; CICs, circulating immune complexes; MHC, major histocompatibility complex; Con A, concanavalin A; ds, double-stranded.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. medium (Nissui Seiyaku Co., Tokyo) that was supplemented with 2 mM L-glutamine (Wako Pure Chemical, Tokyo), penicillin (100 units/ml), streptomycin (100 ug/ml), and 5% human plasma. The cells were cultured in the presence of phytohemagglutinin P (Difco) at 25 pg/ml or of concanavalin A (Con A; Calbiochem) at 5.0 ,ug/ml. (The mitogens had been tested at various doses, and the dose selected was that giving the optimal responses.) The cultures were incubated for 72 hr at 37°C in a humidified atmosphere of 5% C02/95% air.
[3H]Thymidine (0.5 ,Ci in 20 .ul; New England Nuclear; 1 Ci = 37 GBq) was present during the last 4 hr of the culturing period. The 3H radioactivity incorporated into trichloroacetic acid-insoluble material was measured by a liquid scintillation counter.
Generation of Cytotoxic T Lymphocytes. Responder cells (7.5 x 106) and mitomycin C (50 ug/ml)-treated stimulator cells (2.5 x 106) were cocultured in RPMI-1640 medium containing 10% heat-inactivated human serum supplemented with streptomycin (100 pg/mi), penicillin (100 units/ml) and 2-mercaptoethanol (50 tM). After 5 days of coculture in a humidified CO2 incubator, the cells were collected, and their cytotoxic activity was determined by 51Cr-release assay as described (12) .
Measurement of Circulating Immune Complex (CIC). CICs were measured by using microtiter plates coated with complement component Clq as described (13) .
Antibodies to dsDNA. Antibodies to dsDNA were measured by solid-phase binding assay as described (14) .
RESULTS AND DISCUSSION
Autoimmune-prone mice, such as mice of (NZB x NZW) F1, MRL/l, and BXSB strains, show premature thymic involution, including morphological and functional abnormalities (15) (16) (17) . In order to prove why thymic abnormalities develop in autoimmune-prone mice, transplantation of the thymus and bone marrow was performed. When thymuses of newborn MRL/l (H-2") mice were grafted into C3H/HeN nu/nu (H-2") mice, the thymuses of the recipients did not show premature involution even 5 mo after grafting (0/11). By contrast, when thymuses of newborn normal C3H/HeN mice were grafted into MRL/l mice, the thymuses showed premature involution (8/9). Thus, premature thymic involution in autoimmune-prone mice is not intrinsically determined within the thymus but is secondary to other events. When normal bone marrow cells (2 x 107) of young C3H/HeN nu/nu mice were transferred to irradiated young MRL/l mice (<1.5 mo),~~1 ' -~~~~0 .,.k ,, 9#.
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>e.*? S 4; ;+ ' Proc. NatL Acad ScL USA 82 (1985) Histopathological study demonstrated that lymphadenopathy disappeared and that characteristic lymphoid cell infiltrations into the kidney and liver were markedly ameliorated in both MRL/l and BXSB mice that had been reconstituted with bone marrow cells of BALB/c nu/nu mice (Fig. 1 ). An immunofluorescence study revealed that glomerular deposits of IgG (13) . Antibodies to dsDNA were measured by solid-phase binding assay (14) . *9 -* 11, etc., means the BXSB mouse was irradiated at the age of 9 mo (or more as indicated), reconstituted with bone marrow cells of BALB/c nu/nu mice, and sacrificed at the age of 11 mo (or more as indicated), and the serum was used for the assays. t+, Minimal glomerular injury.
tPooled sera from BALB/c (>6 mo) were used as the negative control, and pooled sera from 8-mo-old BXSB and 4-mo-old MRL/I mice were used as positive controls.
component C3 were almost completely absent from the kidneys of these mice.
It is well known that autoimmune-prone mice show high levels of CICs and anti-dsDNA antibodies with age (18, 19) . We measured antibodies to dsDNA and CICs as previously described. As shown in Table 1 , BXSB and MRL/l mice reconstituted with normal bone marrow cells exhibited significantly lower levels of CICs and anti-dsDNA antibodies in comparison with control BXSB and MRL/l mice. The degree of glomerular damagt was correlated with the CIC levels in these mice.
Recently, Wofsy et al. (20) have reported that BXSB3 mice show a progressive increase in the number of peripheral blood monocytes. Following the method they described, we counted the number of monocytes in the peripheral blood of BXSB mice reconstituted with normal bone marrow cells of BALB/c nu/nu mice and compared this number with that of monocytes present in blood of untreated BXSB mice. The number of monocytes in the BXSB mice was reduced to the normal range (<10%), whereas untreated BXSB mice (8 mo old) showed a marked monocytosis (>60%) in the peripheral blood. In addition, polyclonal B-cell hyperactivity in MRL/l and BXSB mice, which hag been reported (10, 18) , also was reduced to normal levels after reconstitution with normal bone marrow across the MHC barriers.
In contrast, T-cell functions were increased as shown in Fig. 2 : untreated MRL/l mice at the age of 3 mo exhibited a high number of Thy-1.2-positive cells in their spleen but a low responsiveness to Con A. However, MRL/l and BXSB mice reconstituted with normal bone marrow cells showed a significantly higher responsiveness to Con A than did untreated controls. Using anti-H-2d, anti-H-2b, and anti-H-2k antisera plus complement, we confirmed that the newly developed T cells in MRL/l and BXSB mice were all derived from stem cells of BALB/c nu/nu mice. The assay for induction of cytotoxic T lymphocytes revealed that the T cells were tolerant to both bone marrow donor-type (BALB/c) and host-type (MRL/l or BXSB) MHC determinants ( Table  2) . These results are consistent with findings (21) (22) (23) (24) In the present study, we used bone marrow cells of young BALB/c nu/nu mice (<2 mo) because we have found that a small number of functional T cells can be detected in spleen of nu/nu mice (12) and that these functional T cells increase with age (25) . The results described here suggest that allogeneic bone marrow transplantation can be used without serious reactions, even when MHC barriers are crossed, provided that the T cells normally present in bone marrow are completely removed. Candidates for treatments for autoimmune diseases include total lymphoid irradiation (26) and employment of immunosuppressive agents such as cyclosporin A (27) , azathioprine (28) , cyclophosphamide (29) , and/or steroid hormones. These approaches, however, exert suppressive effects on T-cell and other immunological functions. With the recent progress of therapy, most patients with autoimmune diseases do not die of renal failure but of opportunistic infection attributable to immunosuppression. Since we provided evidence that T-cell functions increase after bone marrow transplantation in mice, it seems likely with further improvement in bone marrow transplantation technology, which will lead to reducing the mortality rate of the basic procedure and selecting appropriate resistance genes for haplo-identical donors, bone marrow transplantation ultimately might become a viable strategy for the treatment of severe life-threatening autoimmune diseases in humans.
